Stephen D Hall
Overview
Explore the profile of Stephen D Hall including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
121
Citations
3148
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hegde P, Rodriguez B, Bell A, Hall S, Rougee L
Drug Metab Dispos
. 2025 Mar;
53(2):100030.
PMID: 40023571
Current drug discovery screens to assess the drug-drug interaction (DDI) risk caused by time-dependent inhibition (TDI) of cytochrome P450 (CYP) 3A4 are known to overpredict or produce false positives that...
2.
Rougee L, Hegde P, Shin K, Abraham T, Bell A, Hall S
Drug Metab Dispos
. 2025 Jan;
53(1):100006.
PMID: 39884818
Predictions of drug-drug interactions resulting from time-dependent inhibition (TDI) of CYP3A4 have consistently overestimated or mispredicted (ie, false positives) the interaction that is observed in vivo. Recent findings demonstrated that...
3.
Graham D, Mathew S, Marsden J, Smith A, Smerdon G, Hall S
Sci Rep
. 2024 Nov;
14(1):29294.
PMID: 39592811
The CO challenge model (CCM) is a gas inhalation paradigm that provides precisely controlled anxiety induction in experimental settings. Despite its potential as an experimental model of anxiety, our understanding...
4.
Windmill H, Dyer A, Smith A, Roser M, Dhanda A, Hall S
Sci Rep
. 2024 Nov;
14(1):29342.
PMID: 39592657
Sleep profoundly influences human behaviour across cognition, affect, and daily experience. This study evaluated how subjective reports and objective measures of sleep capture the interaction between sleep quality and quantity...
5.
Rhodes E, Gaetz W, Marsden J, Hall S
Brain Sci
. 2024 Oct;
14(10).
PMID: 39451984
Background/objectives: This study investigates the relationship between movement-related beta synchrony and primary motor cortex (M1) excitability, focusing on the time-dependent inhibition of movement. Voluntary movement induces beta frequency (13-30 Hz)...
6.
Anil K, Ganis G, Freeman J, Marsden J, Hall S
Sensors (Basel)
. 2024 Aug;
24(16).
PMID: 39204803
Neurofeedback (NF) is a promising intervention for improvements in motor performance in Parkinson's disease. This NF pilot study in healthy participants aimed to achieve the following: (1) determine participants' ability...
7.
Impact of Heterotropic Allosteric Modulation on the Time-Dependent Inhibition of Cytochrome P450 3A4
Rougee L, Bedwell D, Hansen K, Abraham T, Hall S
Drug Metab Dispos
. 2023 Jul;
51(10):1372-1380.
PMID: 37524542
The current study was designed to investigate the influence of allosteric effectors on the metabolism of the prototypical cytochrome P450 (CYP) 3A4 substrate midazolam (MDZ), and on the determination in...
8.
Pak Y, Posada M, Bacon J, Long A, Annes W, Witcher J, et al.
Pharm Res
. 2023 Jan;
40(11):2499-2511.
PMID: 36635486
Purpose: The objective of this work was to demonstrate that clinical OAT1-mediated DDIs can be predicted using physiologically based pharmacokinetic (PBPK) modeling. Methods: LY404039 is a metabotropic glutamate receptor 2/3...
9.
Anil K, Hall S, Demain S, Freeman J, Ganis G, Marsden J
Brain Sci
. 2021 Oct;
11(10).
PMID: 34679358
Background: Neurofeedback has been proposed as a treatment for Parkinson's disease (PD) motor symptoms by changing the neural network activity directly linked with movement. However, the effectiveness of neurofeedback as...
10.
Mohutsky M, Hall S
Methods Mol Biol
. 2021 Jul;
2342:51-88.
PMID: 34272691
This chapter describes the types of irreversible inhibition of drug-metabolizing enzymes and the methods commonly employed to quantify the irreversible inhibition and subsequently predict the extent and time course of...